Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock: Insider Renee Gala Sells 1,000 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) CEO Renee Gala sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $225.37, for a total value of $225,370.00. Following the completion of the sale, the chief executive officer directly owned 140,394 shares in the company, valued at $31,640,595.78. This trade represents a 0.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $234.76 on Friday. The stock has a market capitalization of $15.24 billion, a P/E ratio of 79.85, a P/E/G ratio of 0.43 and a beta of 0.38. Jazz Pharmaceuticals PLC has a 1 year low of $128.80 and a 1 year high of $266.38. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58. The company’s 50-day moving average is $229.39 and its 200 day moving average is $217.74.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.03) by $0.15. Jazz Pharmaceuticals had a return on equity of 16.55% and a net margin of 4.37%. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.21 billion. During the same quarter in the previous year, the business earned $8.13 earnings per share. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. On average, sell-side analysts expect that Jazz Pharmaceuticals PLC will post 10.88 earnings per share for the current year.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
• Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
• Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on JAZZ shares. Barclays upped their price target on shares of Jazz Pharmaceuticals from $271.00 to $275.00 and gave the stock an “overweight” rating in a report on Tuesday. Morgan Stanley increased their price target on Jazz Pharmaceuticals from $314.00 to $319.00 and gave the stock an “overweight” rating in a research report on Tuesday. The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a research note on Thursday, September 24th. They issued a “buy” rating and a $337.00 price target for the company. UBS Group increased their price target on Jazz Pharmaceuticals from $315.00 to $337.00 and gave the stock a “buy” rating in a research report on Friday, September 11th. Finally, Needham & Company LLC lifted their target price on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $293.45.

Institutional Trading of Jazz Pharmaceuticals

Large investors have recently modified their holdings of the company. Aberdeen Group plc lifted its position in shares of Jazz Pharmaceuticals by 16.5% during the 3rd quarter. Aberdeen Group plc now owns 97,422 shares of the specialty pharmaceutical company’s stock valued at $22,555,000 after acquiring an additional 13,816 shares during the period. JW Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $2,547,000. Russell Investments Group Ltd. boosted its position in Jazz Pharmaceuticals by 50.6% during the third quarter. Russell Investments Group Ltd. now owns 76,421 shares of the specialty pharmaceutical company’s stock worth $17,696,000 after purchasing an additional 25,671 shares in the last quarter. Eurizon Capital SGR S.p.A. lifted its position in shares of Jazz Pharmaceuticals by 46.1% in the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 3,262 shares of the specialty pharmaceutical company’s stock worth $757,000 after buying an additional 1,029 shares during the last quarter. Finally, Maryland State Retirement & Pension System increased its stake in shares of Jazz Pharmaceuticals by 19.0% in the third quarter. Maryland State Retirement & Pension System now owns 3,633 shares of the specialty pharmaceutical company’s stock worth $841,000 after acquiring an additional 580 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.